Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Melexis Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Melexis wird ein jährliches Gewinn- und Umsatzwachstum von 7% bzw. 7.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 34.6% betragen.

Wichtige Informationen

7.0%

Wachstumsrate der Gewinne

7.0%

EPS-Wachstumsrate

Semiconductor Gewinnwachstum19.1%
Wachstumsrate der Einnahmen7.5%
Zukünftige Eigenkapitalrendite34.6%
Analystenabdeckung

Good

Zuletzt aktualisiert06 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Melexis (EBR:MELE) Knows How To Allocate Capital

Jun 07
Melexis (EBR:MELE) Knows How To Allocate Capital

Melexis (EBR:MELE) Seems To Use Debt Quite Sensibly

May 22
Melexis (EBR:MELE) Seems To Use Debt Quite Sensibly

Shareholders Will Probably Be Cautious Of Increasing Melexis NV's (EBR:MELE) CEO Compensation At The Moment

May 08
Shareholders Will Probably Be Cautious Of Increasing Melexis NV's (EBR:MELE) CEO Compensation At The Moment

Calculating The Fair Value Of Melexis NV (EBR:MELE)

Mar 27
Calculating The Fair Value Of Melexis NV (EBR:MELE)

At €78.60, Is Melexis NV (EBR:MELE) Worth Looking At Closely?

Mar 14
At €78.60, Is Melexis NV (EBR:MELE) Worth Looking At Closely?

Many Would Be Envious Of Melexis' (EBR:MELE) Excellent Returns On Capital

Feb 28
Many Would Be Envious Of Melexis' (EBR:MELE) Excellent Returns On Capital

Melexis' (EBR:MELE) Solid Earnings May Rest On Weak Foundations

Feb 15
Melexis' (EBR:MELE) Solid Earnings May Rest On Weak Foundations

Melexis (EBR:MELE) Has A Pretty Healthy Balance Sheet

Jan 02
Melexis (EBR:MELE) Has A Pretty Healthy Balance Sheet

What Does Melexis NV's (EBR:MELE) Share Price Indicate?

Dec 09
What Does Melexis NV's (EBR:MELE) Share Price Indicate?

Here's Why Melexis (EBR:MELE) Has Caught The Eye Of Investors

Nov 27
Here's Why Melexis (EBR:MELE) Has Caught The Eye Of Investors

Melexis (EBR:MELE) Knows How To Allocate Capital

Nov 15
Melexis (EBR:MELE) Knows How To Allocate Capital

Calculating The Intrinsic Value Of Melexis NV (EBR:MELE)

Nov 03
Calculating The Intrinsic Value Of Melexis NV (EBR:MELE)

Melexis' (EBR:MELE) Dividend Will Be €0.91

Oct 10
Melexis' (EBR:MELE) Dividend Will Be €0.91

Melexis (EBR:MELE) Is Due To Pay A Dividend Of €0.91

Sep 26
Melexis (EBR:MELE) Is Due To Pay A Dividend Of €0.91

Does Melexis (EBR:MELE) Have A Healthy Balance Sheet?

Sep 17
Does Melexis (EBR:MELE) Have A Healthy Balance Sheet?

Melexis (EBR:MELE) Has Announced A Dividend Of €0.91

Sep 02
Melexis (EBR:MELE) Has Announced A Dividend Of €0.91

Melexis (EBR:MELE) Has Announced A Dividend Of €0.91

Aug 19
Melexis (EBR:MELE) Has Announced A Dividend Of €0.91

Melexis' (EBR:MELE) Dividend Will Be €0.91

Aug 05
Melexis' (EBR:MELE) Dividend Will Be €0.91

Melexis (EBR:MELE) Might Become A Compounding Machine

Jul 13
Melexis (EBR:MELE) Might Become A Compounding Machine

Do Melexis' (EBR:MELE) Earnings Warrant Your Attention?

Jun 29
Do Melexis' (EBR:MELE) Earnings Warrant Your Attention?

Estimating The Intrinsic Value Of Melexis NV (EBR:MELE)

Jun 02
Estimating The Intrinsic Value Of Melexis NV (EBR:MELE)

At €99.75, Is Melexis NV (EBR:MELE) Worth Looking At Closely?

Apr 11
At €99.75, Is Melexis NV (EBR:MELE) Worth Looking At Closely?

With EPS Growth And More, Melexis (EBR:MELE) Makes An Interesting Case

Mar 27
With EPS Growth And More, Melexis (EBR:MELE) Makes An Interesting Case

Is It Time To Consider Buying Melexis NV (EBR:MELE)?

Jan 09
Is It Time To Consider Buying Melexis NV (EBR:MELE)?

Here's Why Melexis (EBR:MELE) Has Caught The Eye Of Investors

Dec 24
Here's Why Melexis (EBR:MELE) Has Caught The Eye Of Investors

Is Melexis NV (EBR:MELE) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 24
Is Melexis NV (EBR:MELE) Expensive For A Reason? A Look At Its Intrinsic Value

Melexis (EBR:MELE) Is Paying Out A Dividend Of €0.91

Oct 18
Melexis (EBR:MELE) Is Paying Out A Dividend Of €0.91

Melexis' (EBR:MELE) Dividend Will Be €0.91

Oct 04
Melexis' (EBR:MELE) Dividend Will Be €0.91

Melexis' (EBR:MELE) Dividend Will Be €0.91

Sep 20
Melexis' (EBR:MELE) Dividend Will Be €0.91

We Ran A Stock Scan For Earnings Growth And Melexis (EBR:MELE) Passed With Ease

Sep 19
We Ran A Stock Scan For Earnings Growth And Melexis (EBR:MELE) Passed With Ease

Melexis' (EBR:MELE) Dividend Will Be €0.91

Sep 05
Melexis' (EBR:MELE) Dividend Will Be €0.91

Melexis (EBR:MELE) Is Due To Pay A Dividend Of €0.91

Aug 22
Melexis (EBR:MELE) Is Due To Pay A Dividend Of €0.91

Melexis (EBR:MELE) Will Pay A Dividend Of €0.91

Aug 04
Melexis (EBR:MELE) Will Pay A Dividend Of €0.91

Is There An Opportunity With Melexis NV's (EBR:MELE) 31% Undervaluation?

Jul 11
Is There An Opportunity With Melexis NV's (EBR:MELE) 31% Undervaluation?

Melexis (EBR:MELE) Looks To Prolong Its Impressive Returns

Jun 27
Melexis (EBR:MELE) Looks To Prolong Its Impressive Returns

Does Melexis (EBR:MELE) Deserve A Spot On Your Watchlist?

Jun 13
Does Melexis (EBR:MELE) Deserve A Spot On Your Watchlist?

Should You Think About Buying Melexis NV (EBR:MELE) Now?

Mar 01
Should You Think About Buying Melexis NV (EBR:MELE) Now?

Calculating The Fair Value Of Melexis NV (EBR:MELE)

Feb 14
Calculating The Fair Value Of Melexis NV (EBR:MELE)

Melexis (EBR:MELE) Looks To Prolong Its Impressive Returns

Dec 06
Melexis (EBR:MELE) Looks To Prolong Its Impressive Returns

Should You Think About Buying Melexis NV (EBR:MELE) Now?

Nov 18
Should You Think About Buying Melexis NV (EBR:MELE) Now?

Is Melexis NV (EBR:MELE) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 29
Is Melexis NV (EBR:MELE) Expensive For A Reason? A Look At Its Intrinsic Value

Does Melexis (EBR:MELE) Have A Healthy Balance Sheet?

Sep 15
Does Melexis (EBR:MELE) Have A Healthy Balance Sheet?

Melexis (EBR:MELE) Will Be Hoping To Turn Its Returns On Capital Around

Jul 18
Melexis (EBR:MELE) Will Be Hoping To Turn Its Returns On Capital Around

Is It Time To Consider Buying Melexis NV (EBR:MELE)?

Jun 21
Is It Time To Consider Buying Melexis NV (EBR:MELE)?

These 4 Measures Indicate That Melexis (EBR:MELE) Is Using Debt Safely

Jun 08
These 4 Measures Indicate That Melexis (EBR:MELE) Is Using Debt Safely

Melexis NV's (EBR:MELE) Intrinsic Value Is Potentially 20% Below Its Share Price

Apr 11
Melexis NV's (EBR:MELE) Intrinsic Value Is Potentially 20% Below Its Share Price

What Is The Ownership Structure Like For Melexis NV (EBR:MELE)?

Mar 17
What Is The Ownership Structure Like For Melexis NV (EBR:MELE)?

Is Melexis (EBR:MELE) Likely To Turn Things Around?

Feb 28
Is Melexis (EBR:MELE) Likely To Turn Things Around?

Does Melexis (EBR:MELE) Have A Healthy Balance Sheet?

Feb 15
Does Melexis (EBR:MELE) Have A Healthy Balance Sheet?

Gewinn- und Umsatzwachstumsprognosen

ENXTBR:MELE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20261,18225622728211
12/31/20251,08022720726911
12/31/202499920616323711
3/31/2024978211-913N/A
12/31/2023964209-923N/A
9/30/2023938212-747N/A
6/30/2023909204-2142N/A
3/31/2023881199132184N/A
12/31/2022836197148188N/A
9/30/2022779178158194N/A
6/30/2022722166124161N/A
3/31/2022672152105140N/A
12/31/2021644131103142N/A
9/30/202162512295132N/A
6/30/202158410092123N/A
3/31/20215257680109N/A
12/31/2020508697196N/A
9/30/2020487617295N/A
6/30/20204896181104N/A
3/31/20205096775101N/A
12/31/2019487606894N/A
9/30/20195017367105N/A
6/30/2019525884596N/A
3/31/20195471013598N/A
12/31/201856911523100N/A
9/30/2018560114578N/A
6/30/20185411122289N/A
3/31/201852711445106N/A
12/31/2017512111N/A113N/A
9/30/2017499109N/A116N/A
6/30/2017486107N/A96N/A
3/31/201747099N/A108N/A
12/31/201645696N/A108N/A
9/30/201643993N/A116N/A
6/30/201642693N/A134N/A
3/31/201641595N/A127N/A
12/31/201540099N/A115N/A
9/30/201538697N/A109N/A
6/30/201537197N/A103N/A
3/31/201535193N/A97N/A
12/31/201433285N/A95N/A
9/30/201431981N/A95N/A
6/30/201430471N/A84N/A
3/31/201428963N/A80N/A
12/31/201327555N/A71N/A
9/30/201326256N/A57N/A
6/30/201325553N/A56N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MELEDas prognostizierte Gewinnwachstum (7% pro Jahr) liegt über der Sparquote (1.1%).

Ertrag vs. Markt: MELEDie Erträge des Unternehmens (7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Belgian (16.9% pro Jahr).

Hohe Wachstumserträge: MELEDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: MELEDie Einnahmen des Unternehmens (7.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Belgian (6.1% pro Jahr).

Hohe Wachstumseinnahmen: MELEDie Einnahmen des Unternehmens (7.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: MELEDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (34.6%)


Wachstumsunternehmen entdecken